Elite
Series

PT-141 — 10 mg

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist. It was developed from the tanning peptide Melanotan II and has been the subject of clinical trials examining melanocortin pathway activation.

• Two Phase 3 RECONNECT trials (Clayton et al., 2019) examined bremelanotide in premenopausal women, demonstrating statistically significant improvements in Female Sexual Function Index desire domain scores and Female Sexual Distress Scale scores compared to placebo over 24 weeks.
• A Phase 1 study (Diamond et al., 2004) in healthy males documented that PT-141 at doses >7mg produced statistically significant erectile responses compared to placebo, with onset occurring in approximately 30 minutes.
• Research in the Journal of Urology (Safarinejad & Hosseini, 2008) examined PT-141 in men who were non-responsive to sildenafil, finding that 34% of treated subjects reported significantly better outcomes compared to 9% with placebo.
• A 52-week open-label extension study demonstrated a favorable long-term safety profile with sustained efficacy in treating hypoactive sexual desire disorder.

PT-141 activates melanocortin receptors MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors that work peripherally, research suggests melanocortin agonists act through hypothalamic pathways involved in sexual response.

• Clayton AH, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.PMID: PMC6819021
• Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.PMID: 12851303
• Diamond LE, et al. Double-blind, placebo-controlled evaluation of PT-141 in healthy males and patients with erectile dysfunction. Int J Impot Res. 2004;16(1):51-59.PMID: 14963471